Ascletis Pharma (HKSE:01672) Growth Rank : 3 (As of Jun. 05, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma Growth Rank?

Ascletis Pharma has the Growth Rank of 3.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of Ascletis Pharma's Growth Rank

For the Biotechnology subindustry, Ascletis Pharma's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascletis Pharma's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Growth Rank distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's Growth Rank falls into.

Ascletis Pharma Growth Rank Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascletis Pharma (HKSE:01672) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

ASCLF:USA

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. ritonavir tablets, GANOVO, and ASCLEVIR. Geographically, it operates in Mainland China and other countries.

Executives

Jjw12 Limited
Lakemont Holding Llc
Wu Jinzi Jason	2101 Beneficial owner
Wu Judy Hejingdao	2101 Beneficial owner
Jjw11 Limited
C-bridge Capital Gp, Ltd.	2201 Interest of corporation controlled by you
Fu Wei	2201 Interest of corporation controlled by you
Tf Capital Ii Ltd.	2201 Interest of corporation controlled by you
Tf Capital, Ltd.	2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited	2201 Interest of corporation controlled by you
Yang Dan	2201 Interest of corporation controlled by you

Ascletis Pharma (HKSE:01672) Headlines

No Headlines